Hero

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

  • Lead candidate CYAD-01 continues to demonstrate encouraging clinical activity in THINK Phase 1 trial with a new complete response (CR) observed in patient with myelodysplastic syndrome (MDS)
  • Key focus to accelerate the development of CYAD-01 for the treatment of patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) or MDS, including the initiation of a Phase 2 clinical trial during second half 2019

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Letter to Shareholders - January 2019

Letter to Shareholders - January 2019

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Discover all news

Carousel

Social Feed

Celyad's team was present at the CAR-T congress EU. Watch their interview in the highlights of the congress. https://t.co/TFrgMLthWQ

1 week ago

Celyad's team was present at the CAR-T congress EU. Watch their interview in the highlights of the congress. https://t.co/TFrgMLthWQ

#JPM19 >> Listen to @ChristianHomsy, CEO of @CelyadSA discussing partnering & business development in the emerging… https://t.co/vECzGTNW0X

2 weeks ago

#JPM19 >> Listen to @ChristianHomsy, CEO of @CelyadSA discussing partnering & business development in the emerging… https://t.co/vECzGTNW0X

Celyad employees are engaged and highly motivated to develop best-in-class immunotherapies to fight cancer.… https://t.co/Nys3aakscm

2 weeks ago

Celyad employees are engaged and highly motivated to develop best-in-class immunotherapies to fight cancer.… https://t.co/Nys3aakscm

4 days to go until #WorldCancerDay - a time to unite and show your support for those whose lives are affected by ca… https://t.co/mkZsNy8s2q

2 weeks ago

4 days to go until #WorldCancerDay - a time to unite and show your support for those whose lives are affected by ca… https://t.co/mkZsNy8s2q

Celyad's team was present at the CAR-T congress EU. Watch their interview in the highlights of the congress. https://t.co/TFrgMLthWQ

1 week ago

Celyad's team was present at the CAR-T congress EU. Watch their interview in the highlights of the congress. https://t.co/TFrgMLthWQ

#JPM19 >> Listen to @ChristianHomsy, CEO of @CelyadSA discussing partnering & business development in the emerging… https://t.co/vECzGTNW0X

2 weeks ago

#JPM19 >> Listen to @ChristianHomsy, CEO of @CelyadSA discussing partnering & business development in the emerging… https://t.co/vECzGTNW0X

Celyad employees are engaged and highly motivated to develop best-in-class immunotherapies to fight cancer.… https://t.co/Nys3aakscm

2 weeks ago

Celyad employees are engaged and highly motivated to develop best-in-class immunotherapies to fight cancer.… https://t.co/Nys3aakscm

4 days to go until #WorldCancerDay - a time to unite and show your support for those whose lives are affected by ca… https://t.co/mkZsNy8s2q

2 weeks ago

4 days to go until #WorldCancerDay - a time to unite and show your support for those whose lives are affected by ca… https://t.co/mkZsNy8s2q